Richard Lachmann is the author of "First Class Passengers on a Sinking Ship: Elite Politics and the Decline of Great Powers" (Verso 2020), which examines the decline of dominant economic and military powers in early modern Europe and the contemporary United States. He also is the author of "States and Power" (Polity 2010) and "What Is Historical Sociology?" (Polity 2013). He currently is researching media coverage and governmental commemoration of war deaths in the United States and Israel from the 1960s to the present.
“That’s not the image Americans have of their country… it’s a much more positive image of the country being exceptional or the best,”
"It's so underground, and the people doing it know there are dangers to it... they care but it doesn't stop them," said Lander, who wasn't involved with the new research.,In 2015, Brad Lander, PhD, a psychologist and clinical director of addiction medicine at The Ohio State University Wexner Medical Center, worked with computer science students, and a doctoral student to create the Squirrel Smart Recovery app aimed at hero
Dr. Robert Lanford, PhD, is currently the Director of the Southwest National Primate Research Center, one of seven NIH National Primate Research Centers. He is a Scientist at the Texas Biomedical Research Institute and an Adjunct Professor at the University of Texas Health Science Center.
Dr. Robert E. Lanford received a B.S. degree from the University of Texas at Arlington in 1974 and a Ph.D. in Virology from Baylor College of Medicine in 1979. He served as Assistant Professor at Baylor College of Medicine until 1984 when he moved to the Southwest Foundation for Biomedical Research (now Texas Biomedical Research Institute) to initiate programs on the use of nonhuman primates as models for human hepatitis infections. Dr. Lanford has published over 170 scientific papers and serves as a reviewer for several journals. His laboratory performs research on multiple hepatitis viruses HAV, HBV, HCV and GBV-B. One of the primary goals of his research program is to better understand the interactions of the virus with the host, and how these interactions influence either viral clearance or persistence and disease progression. His studies in the chimpanzee were the first to use total genome microarray analysis to examine viral-host interactions and the innate immune response to HCV. In collaboration with pharmaceutical companies, he has utilized the chimpanzee model of chronic HBV and HCV infections to evaluate efficacy of new antiviral therapies as the last preclinical step prior to human clinical trials. These studies contributed to the development of cocktails of antivirals that can now cure HCV infection in 12 weeks. Recently, Dr. Lanford has developed a primate model for liver cancer by the genetic engineering of primary baboon hepatocytes with activated baboon oncogenes and autologous transplantation of the cells to the liver of the immunocompetent hepatocyte donor. Efforts are ongoing in his laboratory to develop new nonhuman primate models for HBV research.
“The chimpanzee is still an extraordinarily important model for medical research—the question is, will we choose to use them or not?”
Research at the Southwest National Primate Research Center (SNPRC) on the campus of Texas Biomedical Research Institute helped advance a new treatment now in human trials for chronic hepatitis B virus (HBV) infection.
Aimee LaPointe Terosky, Ed.D., is an associate professor of educational leadership at Saint Joseph's University and the Director of the IDEPEL Doctoral Program. Dr. Terosky teaches courses in K-12 and Higher Education leadership at the doctoral and masters levels. Prior to her arriving at Saint Joseph's in January 2011, Dr. Terosky was an adjunct assistant professor of higher and postsecondary education at Teachers College, Columbia University, where she taught courses on teaching and learning and faculty development in postsecondary education settings. From 2006-2011, she also served as the assistant principal of Public School #334, The Anderson School in New York City, which received the 2007 New York City Blackboard Award for Outstanding Public Middle School. Areas of expertise: urban principals, faculty careers, women faculty advancement, K-12 and higher education teaching and learning
Larémont is a Carnegie Corporation Scholar on Islam, and a leading expert on political Islam, Islamic law, conflict resolution, democratization, and civil/military relations. His work focuses on North Africa and the Sahel.
Senior Program Manager with ILSI North America managing the programs of several Nutrition Science Committees and developing new concepts into larger scale programs. Nearly 20 years of experience in addressing emerging nutrition issues and application of evidence to policy development. Passionate about engaging stakeholders with diverse perspectives to facilitate dialogue and address issues of common concern to improve health. Previously served as Study Director for the Review of Special Supplemental Nutrition Program for Women, Infants and Children (WIC) Food Packages at the National Academies’ Food and Nutrition Board. Registered dietitian nutritionist (RDN) with a Master of Science degree in nutrition.
By bringing together scientists from industry, academia, and government, the ILSI North America model ensures that nutrition science questions of importance to all sectors are addressed. For example, academic scientists exchange with industry to learn about practical implementation of findings, and government scientists point to the data required to ensure sound policy. Together, these individuals identify research gaps that, when addressed, have the potential to affect the health of the public from bench to consumer product.,Discoveries related to gut microbiota have exploded over the past 10 years. Although the field holds great promise for understanding more about human physiology, this excitement must be tempered by the fact that there do not yet exist best practices for gut microbiome research and methodologies vary from lab to lab. We are at the stage of detecting changes without being able to definitively state the cause or consequence, and in turn, the degree to which any findings can be linked to a
Mark is the Queen's Lead of the £5M Medical Research Council-Cancer Research UK funded Stratified Medicine in Colorectal Cancer Consortium (S:CORT), a UK-wide consortium investigating novel precision medicine approaches in colorectal cancer(CRC). His international reputation in CRC was instrumental in his leading a Critical Gaps in Colorectal Cancer Research Initiative, recently published in the high impact factor journal Gut; this landmark publication has attracted significant global attention (his podcast had the most “hits” of any article in the journal)
Mark is Queen's Lead of the Health Data Research UK Substantive Site, one of only 6 in the UK, which aims to drive innovative precision medicine and public health approaches through the use of Big Data. He is also national lead for Cancer Strategy for HDR-UK. Mark was co-chair of the Cancer Task Team of the Clinical Working Group of the Global Alliance for Genomics and Health (GA4GH), an international cooperative dedicated to effective and responsible sharing of genomic and clinical data. He has authored a number of key papers including a blueprint for cancer date sharing (published in Nature Medicine) and a road map/call to action for a Global Cancer Knowledge Network in the New England Journal of Medicine
Mark has published over 180 papers in international peer review journals, including key papers in the highest impact journals (New Engl J Medicine, Lancet, Nature Medicine, Lancet Oncology, Cancer Discovery, Nature Comms, Gut etc). He is co-lead of an ambitious proposal to develop a Global Innovation Institute in Belfast which will include the One Health Innovation Centre (OHIC), the world’s first Health and Agri-Food Informatics Innovation Centre. Mark’s work has been recognised by a number of national/international awards including the Vander Molen Prize for Leukaemia Research, the Ely Lilly Prize, the St Lukes Medal for Cancer Research and the Graves Medal for Medical Research. He is frequently invited as a guest speaker to international conferences and sits on a number of high level boards/committees at European level including the European Alliance for Personalised Medicine, the Scientific Board of the European Cancer Patient Coalition and the European Cancer Organisation (ECCO) Oncopolicy Forum
Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was the architect of the European Cancer Patient's Bill of Rights (BoR), a catalyst for change and empowerment tool for cancer patients which he launched in the European Parliament on World Cancer Day 2014. The BoR has been adopted across Europe and led to the 70:35 Vision, 70% survival for all cancer patients in Europe by 2035 which was recently adopted by ECCO, the largest interdisciplinary cancer organisation in Europe. Mark’s advocacy work was instrumental in the recent decision to include boys in national UK HPV vaccination programmes. He is also committed to the provision of optimal pathology and laboratory medicine for citizens in resource-limited settings and was senior author of a recent paper in The Lancet as part of The Lancet Series on Pathology and Laboratory Medicine in Low- and Middle- Income Countries.
Neal A. Lester is an expert in African American literary, cultural studies, racial bias and discrimination, especially as regards African Americans.
Lester is a Foundation Professor of English at ASU where he is founding director of the award-winning Project Humanities initiative. He’s also a popular public speaker, radio guest, op-ed contributor, newspaper columnist, blogger, and discussion facilitator. He is the author, co-author or editor of seven books and numerous articles in journal and magazines on topics such as children's literature, drama, folklore, the politics of hair, the "n-word," and racialized images in American cinema. The recipient of dozens of honors and awards for public scholarship and professional service, Lester conducts race and privilege training in the community and leads Project Humanities' Service Saturdays, an outreach to those experiencing homelessness, once per month in downtown Phoenix.
So make this a conversation about language, make it a conversation about race relations, make it a conversation about treating people with kindness.
Dr. Ley joined LJI in 2007 as the founding Division Head of the Division of Inflammation Biology. Dr. Ley received his B.S. from Altkönigschule-Gymnasium, Kronberg, Germany in 1976. In 1982, he received his M.D. from the Julius-Maximilians-Universität, Würzburg, Germany. Dr. Ley began his postdoctoral training from 1983 to 1987 at the Freie Universität Berlin, Germany. From 1987 to 1989, Dr. Ley was a visiting research scientist at the University of California, San Diego and returned to Freie Universität Berlin until 1994, when he joined the faculty of the University of Virginia. From 2001-2007, he was director of the Robert M Berne Cardiovascular Research Center at the University of Virginia.
“If I had known back then what we know now, I would have studied immunology earlier. The immune system is the way to manipulate inflammation, prevent and cure many diseases, including cardiovascular disease.”,“We knew atherosclerosis had an inflammatory component but until recently didn’t have a way to counteract that. We now find that our vaccination actually decreases plaque burden by expanding a class of protective T cells that curb inflammation.”,
Dr. Christina Li received her medical degree from the Columbia College of Physicians and Surgeons. She completed her residency in general surgery at the University of Maryland and was also a research fellow at the Maryland Center for Videoscopic Surgery. She completed a fellowship in minimally invasive and bariatric surgery at the University of Pennsylvania. She has been performing bariatric surgery for LifeBridge Health since 2004 and is a founding member of Sinai Hospital's Bariatric Center for Excellence.
Steven K. Libutti, MD, FACS, was appointed as Director of Rutgers Cancer Institute of New Jersey and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. In addition to his leadership roles within Rutgers University, Dr. Libutti also serves as Senior Vice President of Oncology Services for RWJBarnabas Health, further strengthening the university’s partnership with the healthcare system. He is also a Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics at the Rutgers School of Arts and Sciences Department of Genetics.
Most recently, Dr. Libutti served as Director for the Montefiore Einstein Center for Cancer Care in New York City and was a Professor and Vice Chairman of the Department of Surgery and Professor in the Department of Genetics at Albert Einstein College of Medicine and Montefiore Health System. A surgical oncologist, Dr. Libutti is an internationally known expert in endocrine surgery and the management of neuroendocrine tumors. He is the immediate Past President of the American Association of Endocrine Surgeons. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas.
The recipient of funding from the National Cancer Institute (NCI) for the past 20 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment and blood vessel formation in tumors. He is studying tumor neovascular formation and the interaction between tumor cells, endothelial cells and the components of the tumor microenvironment including fibroblasts and cancer stem cells. His work also focuses on a better understanding of the tumor suppressor genes MEN1 and FILIP1L.
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the NCI in surgical oncology and endocrine surgery. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. He has published over 280 peer reviewed journal articles, is Editor-in-Chief of the Nature Journal Cancer Gene Therapy, and holds seven U.S. patents.
Neuroendocrine tumors, thyroid cancer, parathyroid tumors, pancreatic cancer, liver cancer, gastrointestinal (GI) cancers, minimally invasive surgery, and clinical trials.
“We defined January of 2018 as the start of this integrated model with RWJBarnabas. Prior to that, analytic cancer cases at the cancer institute were around 3,000 a year. In 2018, with this new integrated model across the health system, we are at just over 10,000 combined. And again, to put that in perspective, there are 50,000 new cancer diagnoses a year in the state of New Jersey. So, in 2018, we represented approximately 20 percent of the new cancer diagnoses in the state.”
Dr. Licciardone’s research focuses on the prevention and treatment of chronic pain. He is the first recipient of a Regents Professorship awarded by the Texas College of Osteopathic Medicine since it was established 50 years ago. He also holds the Osteopathic Heritage Foundation Distinguished Chair in Clinical Research in honor of Drs. David Richards and Benjamin Cohen, former President and Provost of the University of North Texas Health Science Center. He presently directs the Osteopathic Research Center, including its PRECISION Pain Research Registry. The latter is the “first-in-the-nation” pain research registry, which studies precision medicine and biopsychosocial approaches to pain management. He received a Midcareer Investigator Award from the National Institutes of Health (NIH), served as an expert panelist for NIH in the area of chronic pain, and completed a four-year term on its National Advisory Council for Complementary and Integrative Health. He directed the OSTEOPATHIC Trial, a five-year study funded by NIH that demonstrated substantial improvements in and recovery from chronic low back pain with osteopathic manipulation. He is presently a Co-Investigator in the $14 million Prevention of Acute to Chronic Back Pain Trial (PACBACK Trial) sponsored by NIH, and recently served on the Work Group that developed NIH’s Federal Pain Research Strategy. Internationally, Dr. Licciardone has served as a consultant to the World Health Organization on regulatory and safety issues relating to osteopathy in Europe and other nations. He gave the keynote address at Advancing Osteopathy 2008, a conference celebrating the 10th anniversary of recognition of osteopaths in the United Kingdom’s National Health Service, including a preconference reception with His Royal Highness, The Prince of Wales. He has also met and advised two former United States Surgeons General on the role of osteopathic physicians within the American health care system. The American Osteopathic Foundation has honored Dr. Licciardone with its Gutensohn-Denslow Award for devoted lifetime service and contributions to research and education within the osteopathic profession.
Dr. David Lintner's main clinical interests are arthroscopic surgery, reconstructive surgery and thrower's injuries. Lintner is the head team physician for the Houston Astros and the team orthopedist for the Houston Texans.
Lipo’s research interests include studying the cultural change of human populations. Lipo uses evolutionary theory as a means of developing methods for studying cultural transmission and the process of natural selection, acting on cultural systems. His work has explored community patterning among prehistoric potters of the Mississippi Valley, patterns of inheritance among stone tools producers in North America and the conditions that led the populations of Easter Island (Rapa Nui, Chili) to construct their famous monumental statues.
In addition to the study of artifact variability and geochronology, Lipo has interests in remote sensing, as a means of efficiently and non-destructively studying the archaeological record. This work includes the use of magnetometry, resistivity, conductivity, thermal imagery, photogrammetry, LiDAR and ground penetrating radar.
Michelle Litchman, PhD, FNP-BC, FAANP, is an expert in diabetes care and using social media and other online resources to monitor how people with diabetes manage their own health in the real world.
Litchman is an Assistant Professor at the College of Nursing and School of Medicine. Her position includes research, teaching, and clinical work at the Utah Diabetes and Endocrinology Center. She is passionate about teaching and precepts health sciences students and teaches didactic courses at the College of Nursing. Dr. Litchman’s program of research emphasizes the social context of chronic disease management across the lifespan with a particular emphasis on diabetes and technology. Her research examines online environments to understand the influence of peer support on health outcomes and diabetes management in the “real-world”. Dr. Litchman also examines family dynamics to understand how diabetes management is supported or derailed, and how technology might be helpful.
"There is a large community that is actively exploring how they can manage their diabetes using off-label solutions,” says Michelle Litchman, Ph.D., FNP-BC, FAANP
Kamala H. Littleton, M.D., is an expert orthopedic surgeon with Orthopedics and Joint Replacement at Mercy Medical Center in Baltimore, Maryland. Board Certified, Dr. Littleton specializes in joint replacement and reconstruction for the hip, knee and shoulder, including:
Anterior hip replacement
MAKO® knee resurfacing and knee replacement
Minimally invasive total knee replacement
Shoulder surgery and reconstruction
Dr. Kamala Littleton is committed to providing her patients some of the best treatment options for their joint, hip, knee and shoulder pain. Dr. Littleton offers years of experience and specialized training to perform anterior hip replacement as well as MAKO knee resurfacing and knee replacement. These innovative orthopedic procedures enable her to help patients reduce their hip or knee pain so they can get back to normal daily activities.
Dr. Kamala Littleton leads The Women’s Orthopedic Program at Mercy, which was developed to focus on the diagnosis and treatment of orthopedic conditions which most frequently affect women. Dr. Littleton recognizes that women have hormonal, anatomical and biomechanical characteristics that make them more vulnerable to certain orthopedic injuries and diseases.
Some of the conditions more common to women include ACL tears, arthritis and osteoporosis. Prevention, treatment and avoiding reoccurrence are Dr. Littleton’s focus when treating women for their joint conditions. Her conservative approach coupled with her surgical expertise make her a top choice for patients seeking relief from hip, knee and shoulder pain.
Losos is an internationally renowned scholar in the field of evolutionary biology. In partnership with the Missouri Botanical Garden and the St. Louis Zoo, Losos leads the Living Earth Collaborative, an academic center dedicated to advancing the study of biodiversity. The Living Earth Collaborative serves as a hub to facilitate interdisciplinary research among plant and animal biologists and other scholars across a wide range of fields, bringing together the world’s leading scholars in the field of biodiversity to address the most pressing issue facing humankind today — the ability to sustain life on Earth.